Use multiplexable genome editing in combination with extensive knowledge in transplantation immunology to create immunologically privileged allogenic cells and xenogeneic organs for use as therapies to treat cancer, organ failure and other important medical conditions
Qihan Biotech announced today that the National Medical Products Administration (NMPA) approved its clinical trial application for the product QN-019a.